Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain. [electronic resource]
Producer: 20150615Description: S13-4 p. digitalISSN:- 1529-8027
- Administration, Oral
- Angiotensin II Type 2 Receptor Blockers -- administration & dosage
- Benzhydryl Compounds -- administration & dosage
- Clinical Trials, Phase II as Topic
- Double-Blind Method
- Female
- Humans
- Isoquinolines -- administration & dosage
- Male
- Multicenter Studies as Topic
- Neuralgia, Postherpetic -- drug therapy
- Pain Measurement
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.